Husten

Quick links to important sections

Husten

Method of action: Antitussive

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Husten

Quick Facts

Property Description
Active Ingredients Diprophylline, Guaifenesin
Common Forms Tablet, Solution, Syrup
Pharmacological Class Bronchodilator and Expectorant/Mucolytic
General Purpose Relief from breathing restriction and congestion
Origin Synthetic derivative

What is Husten and How is it Classified?

Husten is a therapeutic combination drug formulated for oral administration, primarily classified as a bronchodilator and an expectorant/mucolytic agent. It is a synthetic derivative designed to provide symptomatic relief by addressing two distinct issues common in respiratory conditions. This compound formulation offers a comprehensive approach to managing both bronchial obstruction and mucus hypersecretion in one preparation, which distinguishes it from single-entity medicines.


What Active Ingredients Does Husten Contain?

The efficacy of Husten relies on the combined action of its active ingredients: Diprophylline and Guaifenesin. Diprophylline, a Theophylline derivative, provides the bronchodilator effect by helping to open the air passages. Guaifenesin, identified as a Guaiacol glyceryl ether, provides the expectorant and mucolytic function by thinning secretions. The expectorant component, Guaifenesin, works by reducing mucus viscosity, which aids in the clearance of congested material. The formulation provides smooth muscle relaxation capability along with enhanced secretion clearance.


Husten's Purpose and Available Forms

The general purpose of Husten is to ease the discomfort associated with restricted breathing and the accumulation of thick, sticky secretions, which is clinically recognized for improving patient comfort during respiratory episodes. This is achieved by targeting the underlying issues of bronchial obstruction and mucus hypersecretion. The medicine is typically available in several oral dosage forms, including the tablet, solution, and syrup preparations. By promoting wider airways and reducing mucus viscosity, the drug supports effective secretion clearance, simplifying the process of breathing for patients experiencing respiratory difficulty, such as during periods of acute bronchial discomfort.

Regulatory References

  1. Dyphylline (Diprophylline) - LactMed - NCBI/NIH

What side effects are possible with Husten?

Possible Side Effects and Safety Information

The regulatory profile of Husten, a combination of Diprophylline (a Theophylline derivative) and Guaifenesin, documents adverse reactions primarily affecting the gastrointestinal and nervous systems. This information is classified based on official regulatory data to provide a clear understanding of the medicine's safety characteristics.


Officially Documented Adverse Reactions

Adverse effects commonly listed in official labeling include gastrointestinal disturbances such as nausea, vomiting, stomach pain (abdominal pain), and diarrhea. Reactions associated with the nervous system are also categorized as common, including headache, trembling, feeling restless or irritable, and sleep problems (insomnia).

Serious adverse reactions documented in official prescribing information include convulsions (seizures) and signs of a severe allergic reaction, which may involve swelling or difficulty breathing. The cardiac system is also a focus of concern, with documented reports of fast or irregular heartbeat (arrhythmias) and pounding heartbeats.


Safety Restrictions and Special Populations

Official labeling advises caution in patients with certain pre-existing conditions, including a history of seizures, severe heart disease, high blood pressure, liver or kidney disease, overactive thyroid, or a stomach ulcer. The effects of the Theophylline component may be increased by underlying conditions such as heart failure or liver disease. The medication is generally contraindicated in individuals with known hypersensitivity to the active ingredients or related xanthine derivatives.

Specific population-based restrictions are also defined. The medicine is generally not recommended for children younger than 6 years old. Furthermore, the susceptibility to side effects may be increased in newborn infants and older adults (over 60 years of age).

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Husten

Domain Official Regulatory Statement
Documented Overdose Presentations CNS Effects: Seizures (convulsions), tremors, confusion, agitation, nervousness, insomnia. Cardiovascular Effects: Tachyarrhythmias, pounding heartbeats, rapid or irregular heart rate. Gastrointestinal Effects: Nausea, vomiting, abdominal pain, and gastrointestinal bleeding or ulceration. Other signs include muscle twitching, extreme thirst, and high blood sugar (hyperglycemia).
Physiological Systems Affected (as stated in label) Central Nervous System, Cardiovascular System, Gastrointestinal System, and Musculoskeletal System.
Dose-related or Exposure-related Factors (if applicable) Chronic toxicity may occur at lower serum concentrations than those required to induce toxicity in acute overdose.
Population-specific Overdose Notes (if applicable) Increased risk of severe toxicity is officially documented in the elderly and patients with hepatic disease (e.g., cirrhosis) due to altered drug clearance.
Emergency-response statements (as written in official documents) Get emergency medical help or contact a Poison Control Center right away.
When immediate medical help is required (label-derived phrasing only) Prompt medical attention is critical, even if no signs or symptoms are immediately noticeable, or if symptoms such as seizures, severe heart palpitations, or vomiting blood occur.

Overdose Classifications (High-Level)

Classification Official Regulatory Statement
Severity Classification (as defined in official documents) Potentially life-threatening due to the risk of severe neurological events (seizures, status epilepticus) and ventricular arrhythmias, which may lead to cardiac arrest.
Regulatory Basis (EMA / FDA / etc.) FDA DailyMed and corresponding regulatory monographs for the active ingredients.
Overdose-context constraints (as defined in official documents) Management is defined as symptomatic and supportive treatment. No specific antidote is known for this class of compound.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the Husten overdose profile by emphasizing the severe, systemic toxicity risks associated with the xanthine derivative component. This toxicity dictates the regulatory mandate that urgent medical help must be sought immediately following any suspected overdose exposure, as severe manifestations like seizures and cardiac arrhythmias can occur rapidly. The official management approach is defined as purely symptomatic and supportive treatment due to the documented absence of a specific known antidote.

Therapeutic Uses of Husten

Husten is a high-level term for medications relevant in therapeutic domains used in situations involving certain distressing symptoms linked to the respiratory system. These medicines are applied across domains where additional symptomatic support is needed to address a cough—a symptom associated with conditions involving episodic or fluctuating manifestations. This category of agents provides support that helps ease the overall symptom burden. It is applied in clinical settings that involve acute or unstable symptom patterns where short-term symptomatic assistance is often needed.

This approach is commonly used to help with symptoms related to heightened physiological activity in the cough reflex and to assist with symptoms related to inflammatory or irritative states. This supports general well-being during symptomatic phases and is helpful in situations requiring additional symptomatic assistance. These agents may be part of symptomatic management for symptoms related to physical discomfort, symptoms related to inflammatory or irritative states, and symptoms that create noticeable physiological strain. This is relevant when symptoms become temporarily overwhelming, providing supportive relief when symptoms interfere with routine activities.


Quick Fact: Support for Symptom Clusters that may become intense or disruptive.

Regulatory References

  1. NIH MedlinePlus overview of Dextromethorphan

Eligibility and Restrictions for Use

Who can and cannot use Husten?

The eligibility to use Husten (Diprophylline/Guaifenesin) is strictly determined by official regulatory labels, which define mandatory exclusions, age limitations, and conditions requiring caution.

Contraindications and Restrictions

Category Regulatory Status
Allergy/Hypersensitivity Contraindicated in patients with known hypersensitivity to Diprophylline, Guaifenesin, or related xanthine derivatives like Theophylline.
Age Restriction (Pediatric) Contraindicated in children under 12 years for many adult formulations; use in infants under 4 years is not recommended.
Organ Impairment Caution is mandatory for use in patients with severe hepatic (liver) impairment or severe renal (kidney) impairment due to the risk of drug accumulation.
Co-morbid Conditions Requires medical consultation if the patient has a history of heart disease, stomach ulcers, high blood pressure, or an overactive thyroid.

Pregnancy and Lactation

Use is highly restricted during reproductive periods. The drug is classified as Pregnancy Category C (safe use not established), meaning it should only be administered if the potential benefit outweighs the risk. Since the components can pass into breast milk, official guidance requires a decision to discontinue nursing or discontinue the medication.

What should I know about interactions with other medicines?

Husten contains Diprophylline (a xanthine derivative) and Guaifenesin. The official interaction profile is structured around the established regulatory data for theophylline derivatives.

Official Interaction Statements

Classification Regulatory Statements
Exposure-Increasing Co-administration with enzyme inhibitors such as Ciprofloxacin or Cimetidine is documented to reduce clearance, resulting in increased plasma concentration of the Diprophylline component.
Exposure-Decreasing Agents that induce metabolism, including Carbamazepine and the herbal product St. John's Wort, are cited in regulatory data as potentially lowering the drug’s plasma levels.
Additive Effects The combination with Riociguat is contraindicated in official labeling due to the risk of additive hypotension (a pharmacodynamic interaction). Consumption of excessive amounts of caffeine or Guarana may also increase the risk of adverse effects.
Efficacy Reduction Theophylline derivatives are documented to decrease the therapeutic effectiveness of agents such as Adenosine and Regadenoson.

Constraints and Population Notes

  • Lab Test Interference: The Guaifenesin component is officially documented to interfere with certain clinical laboratory determinations, specifically for 5-hydroxyindoleacetic acid (5-HIAA) and vanillylmandelic acid (VMA).
  • Population Notes: Interaction effects may be increased in populations with heart failure, kidney disease, or liver disease (e.g., cirrhosis) due to altered drug clearance, according to regulatory summaries.

This structure reflects the requirements set forth in authoritative government regulatory documents concerning drug–drug, drug–substance, and drug–laboratory test interactions. The profile is defined by metabolic (pharmacokinetic) alterations and synergistic (pharmacodynamic) effects, all of which are cited in official labeling.

Mechanism of Action

Airway Smooth Muscle Tone Modulation

This domain is driven by Diprophylline, which utilizes two complementary molecular pathways to influence the bronchial smooth muscle. The active ingredient acts as an antagonist of adenosine receptors and a non-selective inhibitor of Phosphodiesterase (PDE) enzymes. This dual molecular action elevates intracellular levels of cAMP, which is the biochemical signal for muscle relaxation. The physiological consequence is a direct reduction in intrinsic muscle tone, resulting in the relaxation of bronchial smooth muscle and an increase in the functional airway diameter.


Secretion Rheology Optimization via Neuro-Reflex

Guaifenesin mediates the second mechanistic domain, acting indirectly via the Gastro-Pulmonary Reflex. By stimulating afferent nerve endings in the gastric mucosa, a vagal reflex is triggered, which signals the respiratory glands to increase the volume and hydration of their output. This physiological cascade directly alters the physical properties of the mucus, decreasing its viscosity and adhesiveness, which enhances the rate of mucociliary transport.


Mechanistic Synergy for Efficient Airway Clearance

The final physiological outcome is achieved through the synergy of these two distinct mechanisms. Diprophylline modulates the structural mechanism of bronchial smooth muscle tone, while Guaifenesin modulates the physical mechanism of secretion rheology. The mechanism provides a dual action that simultaneously modulates the bronchial smooth muscle tone and the viscoelasticity of airway contents.

Dosage and Administration Information

How to Use Husten

The administration of Husten, a therapeutic combination of Diprophylline and Guaifenesin, is restricted exclusively to the oral route, with formulations available as immediate-release tablets and oral solutions or syrups. The medicine is intended for short-term, intermittent use corresponding to acute symptomatic episodes.


Standard Dosing Regimens

For adults and adolescents, the dosing pattern for immediate-release (IR) formulations is typically one tablet three to four times daily, or 15 mL of oral solution every six hours. The dosage may be doubled as needed in severe cases, reflecting an adjustment principle for the combination product. For the Guaifenesin component, a maximum of 2,400 mg should not be exceeded in a 24-hour period.


Administration Context and Special Rules

Husten may be taken without regard to the timing of meals, although taking it postprandially may mitigate potential gastrointestinal discomfort. A key procedural instruction is the recommendation to drink extra fluids to enhance the action of the Guaifenesin component.

If the medication is supplied as an extended-release tablet, it must be swallowed whole and must not be crushed, chewed, or broken, which is necessary to maintain the integrity of its controlled-release mechanism. Doses of the liquid formulation must be accurately measured using a specialized device.

Regarding missed timing, if a dose is skipped, it should be taken immediately unless it is almost time for the next scheduled dose, in which case the missed dose must be skipped. A double dose is strictly prohibited.

In older adults, initial therapy may commence at the lower end of the dosing range, and the use of the medicine requires caution in patients with severe hepatic or renal impairment due to the risk of accumulation. The combination product is not generally recommended for children under 6 years old.

Recent Clinical Evidence

Research evidence / Overview of studies for Husten

The research on Husten, a medicine combining Diprophylline and Guaifenesin, is aimed at understanding how symptoms were measured and evolved in study populations associated with specific respiratory conditions. This overview summarizes the structure of the existing scientific evidence, including what has been studied and where the current research landscape has limitations, using information from regulatory and peer-reviewed sources.


Evidence for Use in Chronic Bronchospastic and Obstructive Disorders

The primary research for this combination medicine was conducted in contexts involving conditions characterized by fluctuating or episodic manifestations where airway limitations and secretions were present in the study populations. Studies explored the medicine in adults, with research examining subjects during periods of increased symptom activity. The clinical evaluation involved short-term Randomized Controlled Trials (RCTs). Findings often describe patterns of measurement observed in the studies, such as recorded differences in lung function parameters, which research explored as an axis of effect. Long-term effects are not fully established, and comparative evidence is also limited.

Studies Examining Symptom Scores and Expectorant Effects

Research exploring this axis was applied in studies examining patient-reported experiences related to chest congestion and cough. Findings describe patterns observed in the studies where patients reported how symptoms evolved, but certainty remains low and the reported data are still emerging on the Guaifenesin ingredient within the combination.


Evidence for Use in Acute Respiratory Tract Congestion

The evidence in this area focuses primarily on the Guaifenesin ingredient, and research was conducted in contexts involving conditions involving periods of heightened symptoms, such as those associated with the common cold. Follow-up durations typically limited to 5 to 7 days. Findings were mixed across some studies regarding symptomatic change compared to a placebo, indicating that evidence quality varies across studies.


What the Research Landscape Suggests is Still Uncertain

The results apply only to the populations studied, and the evidence quality varies across studies. Long-term effects are not fully established, as follow-up durations were limited across the core efficacy trials. Data for children under 6 years old remain insufficient, and this specific age group is often excluded from studies.

Key Studies & References

  1. Role of guaifenesin in the management of chronic bronchitis and upper respiratory tract infections
  2. Comparing the efficacy and safety of theophylline with doxofylline in patients with chronic obstructive pulmonary disease

Frequently Asked Questions (FAQ)

Common questions about Husten (FAQ)

Q: How quickly should I expect Husten to start working?

Official information indicates that the expectorant component, Guaifenesin, typically begins its effect in approximately 30 minutes after taking the medicine. The bronchodilating component, Diprophylline, also begins working within a similar timeframe and is intended to provide relief from symptoms while the drug is active in the body.

Q: How long do the effects of Husten typically last?

The duration of effect for the expectorant component of Husten is generally considered to be about four to six hours. This duration is consistent with the recommended interval for taking immediate-release forms of the medication.

Q: What kind of cough is Husten intended to treat?

Husten is indicated for coughs associated with chest congestion and bronchial irritation that involve the production of excessive, thick mucus. It is designed to help loosen phlegm and thin secretions, which may assist in the clearance of mucus via coughing.

Q: Is Husten available over-the-counter or does it require a prescription?

While the Guaifenesin component alone is often available over-the-counter (OTC), the combination product of Diprophylline and Guaifenesin is typically classified as a prescription-only medication in many jurisdictions.

Q: What are the signs of a serious or allergic reaction to Husten?

Official labeling warns that serious adverse reactions may include convulsions (seizures) or signs of a severe allergic reaction. These signs can include hives, difficulty breathing, or swelling of the face, lips, or throat. A fast, pounding, or irregular heartbeat is also listed as a serious reaction.

Q: How should I store Husten to keep it effective?

Official labeling requires Husten to be stored at a controlled room temperature, typically between 20 C and 25 C (68 F and 77 F), in its original, closed container. It must also be protected from direct heat, moisture, and freezing.

Q: Is it safe to take Husten if I have high blood pressure?

Regulatory information advises that Husten should be used with caution in individuals who have high blood pressure (hypertension). This warning is due to the potential stimulant effects of the Diprophylline component. Medical consultation is generally advised to assess the suitability of its use.

Q: Does Husten contain any known allergens?

The medicine is strictly contraindicated for anyone with a known hypersensitivity or allergy to the active ingredients (Diprophylline, Guaifenesin) or related compounds. The full list of inactive ingredients, which may contain common manufacturing allergens, is detailed in the medication’s official leaflet.

Q: Can Husten be taken with common cold and flu medications?

Official guidelines advise caution when combining Husten with common cold and flu medications. Many of these products contain stimulants, cough suppressants, or other active ingredients that could lead to additive effects or drug interactions. A review of the full ingredient list of all products with a healthcare provider is generally recommended.

Q: Does Husten interact with common pain relievers like ibuprofen or acetaminophen?

Generally, there are no known significant interactions documented between the active ingredients of Husten and simple over-the-counter pain relievers such as Ibuprofen or Acetaminophen. However, a review of all current medications with a healthcare professional is generally recommended.

Q: Can people with diabetes safely take Husten?

Patients with diabetes should note that some liquid or syrup formulations of Husten may contain sugar, alcohol, or other sweeteners as inactive ingredients. These could potentially affect blood glucose levels. The suitability of the medication depends on the specific formulation and the patient's overall health status.

Q: Is it possible to develop a tolerance to Husten over time?

The official product label does not typically include specific warnings regarding the development of tolerance or dependence, as the drug is only indicated for short-term, acute use.

Q: Is it normal to feel a tingling sensation after taking Husten?

The official adverse reaction profile lists trembling and restlessness among the common nervous system-related side effects. Some product labels also include flushing (a warm, red, or tingly feeling) as a documented effect.

Q: Does Husten have any known interactions with herbal supplements?

The regulatory profile explicitly documents an interaction with the herbal product St. John's Wort, which can lower the concentration of the drug. The interaction profile suggests that all herbal supplements should be reviewed with a healthcare provider due to potential interactions.

Q: Are there any restrictions on activity while taking Husten?

Due to the potential for nervous system side effects such as dizziness, restlessness, or sleep problems, activities that require complete mental alertness, such as driving or operating heavy machinery, are often advised to be avoided until the patient knows how the medication affects them.

Q: Does the time of day matter when taking Husten?

While the dosage schedule is most important, patients who experience sleep problems (insomnia) or restlessness as a side effect may find it advisable to avoid taking a dose too close to their bedtime.

Q: Is it true that Husten can cause insomnia for some people?

Yes, sleep problems (insomnia) and a feeling of restlessness are listed among the common adverse reactions documented in the official prescribing information for the Diprophylline component of Husten.

Q: What is the difference between the liquid and tablet forms of Husten?

The oral solution (liquid) is typically an immediate-release formulation, whereas the tablet form may be available as both immediate-release and extended-release. Extended-release tablets must be swallowed whole to ensure the active ingredients are released correctly over time.

Q: Why might a doctor prescribe Husten over a different cough medicine?

Husten is a combination product that provides a dual mechanism of action, containing both a bronchodilator and an expectorant. It is often used when a combination product is desired to address both airway constriction and mucus production simultaneously.

Q: Can Husten be used for a smoker's cough?

Official labeling states that any persistent cough, such as one associated with smoking, should be evaluated by a healthcare provider before the medication is used. The expectorant component is specifically intended for coughs that involve excessive phlegm.

Q: What are the main risks of long-term use of Husten?

Husten is approved and indicated only for short-term, acute use. Regulatory reviews indicate that long-term effects of the combination have not been fully established. The medication is not intended for use beyond the recommended short-term duration.

Q: Is Husten effective for coughs caused by allergies?

Husten is indicated for cough and congestion associated with bronchial irritation and mucus production. If an allergic reaction results in these specific symptoms, the medication may be expected to offer symptomatic relief. However, it is not an anti-allergy treatment.

Q: Why do some people use Husten even if they don't have a cold?

The medication is officially indicated for the symptomatic relief of conditions such as chronic obstructive pulmonary disease (COPD), bronchitis, and asthma, where the combined effects of reducing bronchial constriction and clearing mucus are required.

Q: Does Husten contain pseudoephedrine or any similar stimulants?

The active ingredients in Husten are Diprophylline (a mild stimulant in the xanthine class) and Guaifenesin. The combination product does not contain the decongestant ingredient Pseudoephedrine.

Q: What is the shelf life of Husten once the bottle is opened?

While the manufacturer provides an original expiration date, regulatory guidelines for liquid or syrup medications often recommend discarding the product within three to six months after the bottle has been opened to ensure safety and potency.

Q: Are there known interactions between Husten and common antidepressants?

Due to the metabolic pathways involved, xanthine derivatives like Diprophylline may interact with certain antidepressants. It is always recommended to review all prescribed medications, including antidepressants, with a healthcare professional due to potential interactions.

Q: Is it possible for Husten to mask the symptoms of a more serious illness?

Official warnings advise patients to discontinue use and consult a doctor if the cough persists for more than seven days, returns, or is accompanied by a fever, rash, or persistent headache. These signs may indicate an underlying serious illness.

Q: Does Husten work better if taken with food or on an empty stomach?

According to the official product information, Husten may be taken without regard to the timing of meals. However, taking the medication after eating may help to mitigate or reduce any potential gastrointestinal discomfort.

Q: Can Husten interact with birth control pills?

The official product label does not specifically list birth control pills as a documented interaction. Nevertheless, patients are advised to discuss all current medications, including oral contraceptives, with a healthcare provider.

Q: Is Husten safe for people with kidney or liver problems?

Regulatory information mandates caution for its use in patients with severe hepatic (liver) or severe renal (kidney) impairment due to the increased risk of drug accumulation. The decision for its use is based on a medical assessment.

Q: Does Husten interact with caffeine?

Yes, official labeling includes a warning that consuming excessive amounts of caffeine or products containing Guarana may increase the risk of adverse effects. This is due to the Diprophylline component having additive stimulant properties.

Q: Is the side effect of dry mouth common with Husten?

Dry mouth is not typically listed among the common adverse effects documented for the Husten combination product. The most frequently reported side effects primarily involve the nervous system and the stomach.

How should Husten be stored and disposed of?

Husten requires specific storage and disposal procedures as outlined in regulatory documentation.


Storage Conditions

Temperature: Store at controlled room temperature between 20 C and 25 C (68 F and 77 F). The medicine must be protected from freezing, as this may affect liquid preparations.

Protection: Keep Husten in its original, closed container and store it away from heat, moisture, and direct light.

Safety: The product must be stored out of the reach and sight of children.


Disposal Instructions

Expired or Unused Product: Do not keep outdated medicine. Consult a pharmacist or healthcare provider for the best way to dispose of any unused or expired Husten. It should generally not be disposed of in wastewater or household waste; utilize a drug take-back program where available.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Husten found in:

A-Z Index: